CRISPR Therapeutics AG
CRSP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $4,235 | $2,924 | $3,364 |
| - Cash | $286 | $197 | $235 | $298 |
| + Debt | $193 | $215 | $219 | $224 |
| Enterprise Value | – | $4,253 | $2,909 | $3,289 |
| Revenue | $1 | $0 | $1 | $35 |
| % Growth | – | -100% | -97.5% | – |
| Gross Profit | -$64 | -$45 | -$57 | $35 |
| % Margin | -7,177.1% | – | -6,548.4% | 100% |
| EBITDA | -$101 | -$225 | -$144 | -$60 |
| % Margin | -11,404.8% | – | -16,611.3% | -170.7% |
| Net Income | -$106 | -$209 | -$136 | -$37 |
| % Margin | -11,973.1% | – | -15,722.1% | -106.6% |
| EPS Diluted | -1.17 | -2.4 | -1.58 | -0.44 |
| % Growth | 51.3% | -51.9% | -259.1% | – |
| Operating Cash Flow | -$85 | -$114 | -$54 | -$50 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$85 | -$114 | -$54 | -$50 |